Trial Profile
Incidence of cardiovascular events after long term exposure to Nilotinib in Chronic Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 29 Jul 2018 New trial record